LANCET GASTROENTEROLOGY & HEPATOLOGY, cilt.7, sa.1, ss.17-27, 2022 (SCI-Expanded)
Background Etrolizumab is a gut-targeted anti-beta 7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis.